Chapter title |
The Three-Decade Long Journey in Heart Failure Drug Development
|
---|---|
Chapter number | 101 |
Book title |
Heart Failure
|
Published in |
Handbook of experimental pharmacology, January 2016
|
DOI | 10.1007/164_2016_101 |
Pubmed ID | |
Book ISBNs |
978-3-31-959658-7, 978-3-31-959659-4
|
Authors |
Kelly S. Lewis, Javed Butler, Johann Bauersachs, Peter Sandner |
Abstract |
Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This paper will briefly summarize the burden of disease, HF classification and definitions and the landmark clinical trials in both HFrEF and HFpEF. Given the increasing incidence and prevalence of HF and the high morbidity and mortality associated with this disease, continued development efforts are essential to address the unmet needs of these patients. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 28 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 21% |
Student > Ph. D. Student | 4 | 14% |
Student > Doctoral Student | 2 | 7% |
Researcher | 2 | 7% |
Student > Master | 2 | 7% |
Other | 1 | 4% |
Unknown | 11 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 21% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Unspecified | 1 | 4% |
Agricultural and Biological Sciences | 1 | 4% |
Other | 3 | 11% |
Unknown | 14 | 50% |